Kymera Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Kymera Therapeutics

09/05/2025 14:31

Kymera Therapeutics Inc KYMR.OQ reported a quarterly adjusted loss of 82 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -62 cents.  The mean expectation of sixteen analysts for the quarter was for a loss of 92 cents per share. Wall Street expected results to range from $-1.07 to -76 cents per share.

Revenue rose 114.8% to $22.10 million from a year ago; analysts expected $10.15 million.

Kymera Therapeutics Inc's reported EPS for the quarter was a loss of 82 cents​.

The company reported a quarterly loss of $65.58 million.

Kymera Therapeutics Inc shares had risen by 12.4% this quarter and lost 23.5% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 16.9% in the last three months.​

In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Kymera Therapeutics Inc is $56.50

This summary was machine generated from LSEG data May 9 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.92
-0.82
Beat
Dec. 31 2024
-0.77
-0.88
Missed
Sep. 30 2024
-0.84
-0.82
Beat
Jun. 30 2024
-0.68
-0.58
Beat